

DAFTAR PUSTAKA

- Abu Hassan SO, Petersen PH, Lund F, Nielsen DL, Tuxen MK, Sölétormos G. 2015. Monitoring performance of progression assessment criteria for cancer antigen 125 among patients with ovarian cancer compared by computer simulation. *Biomark Med.* 9(9):911-22.
- Alcázar, J.L, Utrilla-Layna, J, Mínguez, J.Á, Jurado, M. 2013. Clinical and ultrasound features of type I and type II epithelial ovarian cancer. *Int. J. Gynecol. Cancer*, 23, 680–684.
- Alsop, K, Fereday, S, Meldrum, C, DeFazio, A, Emmanuel, C, George, J, Dobrovic, A, Birrer, M.J, Webb, P.M, Stewart, C, et al. 2012. BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: A report from the Australian ovarian cancer study group. *J. Clin. Oncol.* 30, 2654–2663
- Amate, P, Huchon, C, Dessapt, A.L, Bensaid, C, Medioni, J, Le Frère Belda, M.A, Bats, A.S, Lécuru, F.R. 2013. Ovarian cancer: Sites of recurrence. *Int. J. Gynecol. Cancer.* 23, 1590–1596.
- American Cancer Society. Survival Rates for Ovarian Cancer. 2019. <https://www.cancer.org/cancer/ovarian-cancer/detection-diagnosis-staging/survival-rates.html>
- American College of Obstetricians and Gynecologists. ACOG Committee Opinion: number 280, December 2002. The role of the generalist obstetrician-gynecologist in the early detection of ovarian cancer. *Obstet Gynecol.* 2002 Dec;100(6):1413-6
- American College of Obstetricians and Gynecologists. 2015. Salpingectomy for ovarian cancer prevention committee opinion no 620. *Obstet Gynecol*; 125: 279-81
- Andersen, M.R., Goff, B.A., Lowe, K.A., Scholler, N., Bergan, L., Drescher, C.W., Paley, P., Urban, N., 2010. Use of a Symptom Index, CA125, and HE4 to predict ovarian cancer. *Gynecol oncol* 116, 378–83. <https://doi.org/10.1016/j.ygyno.2009.10.087>

- Andi, F., Zulkifly, A., Syamsiar, S. 2011. Faktor Risiko Kanker Ovarium di RSUP Wahidin Sudirohusodo. Makassar.
- Armstrong, Deborah K. 2020. "189. Gynaecologic cancers: ovarian cancer". In Goldman, Lee; Schafer, Andrew I. (eds.). Goldman-Cecil Medicine. Vol. 1 (26th ed.). Philadelphia: Elsevier. pp. 1332–1335.
- Arora N, Talhouk A, McAlpine JN, Law MR, Hanley GE. 2018. Longterm mortality among women with epithelial ovarian cancer: a population-based study in British Columbia, Canada. BMC Cancer. 18(1): 1039.doi:10.1186/s12885-018-4242-8
- Atallah GA, Kampan NC, Chew KT, Mohd Mokhtar N, Md Zin RR, Shafiee MNB, Abd Aziz NHB. 2023. Predicting Prognosis and Platinum Resistance in Ovarian Cancer: Role of Immunohistochemistry Biomarkers. Int J Mol Sci, Jan 19;24(3):1973. doi: 10.3390/ijms24031973. PMID: 36768291; PMCID: PMC9916805.
- Aziz MF. 2009. Gynecological cancer in Indonesia. J Gynecol Oncol 2009; 20: 8-10
- Babaier, A., Ghatage, P. 2020. Mucinous Cancer of the Ovary: Overview and Current Status. Diagnostics 10, 52. <https://doi.org/10.3390/diagnostics10010052>
- Babic A, Cramer DW, Kelemen LE, Köbel M, Steed H, Webb PM, Johnatty SE, deFazio A, Lambrechts D, Goodman MT, Heitz F, Matsuo K, Hosono S, Karlan BY, Jensen A, Kjær SK, Goode EL, Pejovic T, Moffitt M, Høgdall E, Høgdall C, McNeish I, Terry KL. 2017. Predictors of pretreatment CA125 at ovarian cancer diagnosis: a pooled analysis in the Ovarian Cancer Association Consortium. Cancer Causes Control, May;28(5):459-468. doi: 10.1007/s10552-016-0841-3. Epub 2017 Jan 3. PMID: 28050675; PMCID: PMC5593071.
- Baert T, Van Camp J, Vanbrabant L, Busschaert P, Laenen A, Han S, Van Nieuwenhuysen E, Vergote I, Coosemans A. 2018. Influence of CA125, platelet count and neutrophil to lymphocyte ratio on the immune system of ovarian cancer patients. Gynecol Oncol, Jul;150(1):31-37. doi: 10.1016/j.ygyno.2018.05.004. Epub 2018 May 9. PMID: 29751991.

- Baker, Vicki V. 2001. Treatment Options for Ovarian Cancer. *Clinical Obstetrics & Gynecology*. 44(3):522-530.
- Bast, J.; Xu, F.J.; Yu, Y.H.; Barnhill, S.; Zhang, Z.; Mills, G.B. 1998. CA 125: The past and the future. *Int. J. Biol. Markers*, 13, 179–187.
- Beeghly-Fadiel A, Wilson AJ, Keene S, et al. 2018. Differential cyclooxygenase expression levels and survival associations in type I and type II ovarian tumors. *J Ovarian Res*. 11(1):17.
- Bertelsen K, Grenman S, Rustin GJ. 1999. How long should first-line chemotherapy continue? *Ann Oncol*. 10 Suppl 1:17-20.
- Booth, Christopher M.; Eisenhauer, Elizabeth A. 2012. Progression-Free Survival: Meaningful or Simply Measurable?. *Journal of Clinical Oncology*. 30 (10): 1030–1033. doi:10.1200/JCO.2011.38.7571
- Bryant A, Hiu S, Kunonga PT, Gajjar K, Craig D, Vale L, Winter-Roach BA, Elattar A, Naik R. 2022. Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after primary surgery. *Cochrane Database Syst Rev*, Sep 26;9(9):CD015048. doi: 10.1002/14651858.CD015048.pub2. PMID: 36161421; PMCID: PMC9512080.
- Budiana NG. 2014. Tumor ovarium: prediksi keganasan prabedah. *Medicina*, 44.
- Budiana, I.N., Angelina, M. and Pemayun, T.G. 2019. Ovarian cancer: Pathogenesis and current recommendations for Prophylactic Surgery, *Journal of the Turkish-German Gynecological Association*, 20(1), pp. 47–54. doi:10.4274/jtgga.galenos.2018.2018.0119
- Buyse M. 2009. Use of meta-analysis for the validation of surrogate endpoints and biomarkers in cancer trials. *Cancer Journal*. 15(5):421-425. doi:10.1097/PPO.0b013e3181b9c602
- Cannistra SA. 2004. Cancer of the ovary. *N Engl J Med* 351:2519–2529
- Calderon-Margalit R, Friedlander Y, Yanetz R, et al. 2008. Cancer risk after exposure to treatments for ovulation induction. *Am J Epidemiol*. 169(3):365–375. doi:10.1093/aje/kwn318

- Ceran MU, Tasdemir U, Colak E, Güngör T. 2019. Can complete blood count inflammatory parameters in epithelial ovarian cancer contribute to prognosis? - a survival analysis. *J Ovarian Res.* 12(1):16.
- Charkhchi, P. et al. 2020. CA125 and ovarian cancer: A comprehensive review, *Cancers*, 12(12), p. 3730. doi:10.3390/cancers12123730.
- Chi, D.S, Eisenhauer, E.L, Lang, J, Huh, J, Haddad, L, Abu-Rustum, N.R, Sonoda, Y, Levine, D.A, Hensley, M, Barakat, R.R. 2006. What is the optimal goal of primary cytoreductive surgery for bulky stage IIIc epithelial ovarian carcinoma (EOC)? *Gynecol. Oncol.* 103, 559–564.
- Chi, D.S, Musa, F, Dao, F, Zivanovic, O, Sonoda, Y, Leitao, M.M, Levine, D.A, Gardner, G.J, Abu-Rustum, N.R, Barakat, R.R. 2012. An analysis of patients with bulky advanced stage ovarian, tubal, and peritoneal carcinoma treated with primary debulking surgery (PDS) during an identical time period as the randomized EORTC-NCIC trial of PDS vs neoadjuvant chemotherapy (NACT). *Gynecol. Oncol.* 124, 10–14.
- Cheon DJ, Li AJ, Beach JA, et al. 2015. ADAM12 is a prognostic factor associated with an aggressive molecular subtype of high-grade serous ovarian carcinoma. *Carcinogenesis.* 36(7):739-747.
- Chen J, Liu Z, Fang S, et al. 2015. Fibulin-4 is associated with tumor progression and a poor prognosis in ovarian carcinomas. *BMC Cancer.* 15:91.
- Chornokur G, Amankwah EK, Schildkraut JM, Phelan CM. 2013. Global ovarian cancer health disparities. *Gynecol Oncol.* 129(1):258–264. doi:10.1016/j.ygyno.2012.12.016
- Clark T G, Stewart M E, Altman D G, et al. 2001. A prognostic model for ovarian cancer. *British Journal of Cancer.* 85(7): 944-952.
- Clarke-Pearson, D.L. 2009. Clinical practice. Screening for ovarian cancer. *N. Engl. J. Med.* 361, 170–177
- Cooper BC, Sood AK, Davis CS, Ritchie JM, Sorosky JI, Anderson B, Buller RE. 2002. Preoperative CA 125 levels: an independent prognostic factor for epithelial ovarian cancer. *Obstet Gynecol*

- Corrado, G, Salutari, V, Palluzzi, E, Distefano, M.G, Scambia, G, Ferrandina, G. 2017. Optimizing treatment in recurrent epithelial ovarian cancer. *Expert Rev. Anticancer Ther*, 17, 1147–1158.
- Cottreau CM, Ness RB, Modugno F, Allen GO, Goodman MT. 2003. Endometriosis and its treatment with danazol or lupron in relation to ovarian cancer. *Clin Cancer Res*, 9(14):5142–5144.
- Cress, R.D, Chen, Y.S, Morris, C.R, Petersen, M, Leiserowitz, G.S. 2015. Characteristics of long-term survivors of epithelial ovarian cancer. *Obs. Gynecol*, 126, 491–497.
- Cymbaluk-Płoska A, Chudecka-Głaz A, Pius-Sadowska E, Machaliński B, Menkiszak J, Sompolska-Rzechuła A. 2018. Suitability assessment of baseline concentration of MMP3, TIMP3, HE4 and CA125 in the serum of patients with ovarian cancer. *J Ovarian Res*, 11(1):1.
- Daly M, Drescher CW, Yates MS, Jeter JM, Karlan BY, Alberts DS, et al. 2015. Salpingectomy as a means to reduce ovarian cancer risk. *Cancer Prev Res (Phila)*, 8: 342-8.
- De Leo, A, Santini, D, Ceccarelli, C, Santandrea, G, Palicelli, A, Acquaviva, G, Chiarucci, F, Rosini, F, Ravegnini, G, Pession, A, et al. 2021. What Is New on Ovarian Carcinoma: Integrated Morphologic and Molecular Analysis Following the New 2020 World Health Organization Classification of Female Genital Tumors. *Diagnostics*, 11,697. <https://doi.org/10.3390/diagnostics11040697>
- Dharmarajan, Adarsh et al. 2020. Dynamic analysis of serum Ca-125 levels during neoadjuvant chemotherapy in patients with advanced epithelial ovarian cancer: a retrospective study. *International journal of reproduction, contraception, obstetrics and gynecology*, n. pag.
- Dobrzycka B, Mackowiak-Matejczyk B, Terlikowska KM, Kulesza-Bronczyk B, Kinalski M, Terlikowski SJ. 2015. Prognostic significance of pretreatment VEGF, survivin, and Smac/DIABLO serum levels in patients with serous ovarian carcinoma. *Tumour Biol*, 36(6):4157-4165.
- Doubeni, C.A., Doubeni, A.R., Myers, A.E. 2016. Diagnosis and Management of Ovarian Cancer. *Am Fam Physician* 93, 937–44

- Du Bois, A, Reuss, A, Pujade-Lauraine, E, Harter, P, Ray-Coquard, I, Pfisterer, J. 2009. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: A combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials. *Cancer*, 115, 1234–1244.
- Enakpene, C.A, Omigbodun, A.O, Goecke, T.W, Odukogbe, A.T, Beckmann, M.W. 2009. Preoperative evaluation and triage of women with suspicious adnexal masses using risk of malignancy index. *J. Obstet. Gynaecol. Res*, 35, 131–138
- Erzen M, Kovacic J. 1998. Relationship between endometriosis and ovarian cancer. *Eur J Gynaecol Oncol*, 19(6):553–555
- Feng Z, Wen H, Bi R, et al. 2016. Preoperative Neutrophil-to-Lymphocyte Ratio as a Predictive and Prognostic Factor for High-Grade Serous Ovarian Cancer. *PLoS One*, 11(5): e0156101.
- Ferlay. J, Colombet. M, Soerjomataram, I, Mathers, C, Parkin, D.M, Piñeros, M, Znaor, A, Bray, F. 2019. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. *Int. J. Cancer*, 144, 1941–1953
- Franceschi S, La Vecchia C, Booth M, et al. 1991. Pooled analysis of 3 European case-control studies of ovarian cancer: II. Age at menarche and at menopause. *Int J Cancer*, 49(1):57–60
- Gadducci A, Zola P, Landoni F, et al. 1995. Serum half-life of CA 125 during early chemotherapy as an independent prognostic variable for patients with advanced epithelial ovarian cancer: results of a multicentric Italian study. *Gynecol Oncol*, 58(1):42-47.
- Gandhi T, Zubair M, Bhatt H. 2022. Cancer Antigen 125. [Updated 2022 Nov 23]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan-. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK562245/>
- Ganesan P, Kumar L, Hariprasad R, Gupta A, Dawar R, Vijayaraghavan M. 2008. Improving care in ovarian cancer: the role of a clinico-pathological meeting. *Natl Med J India*, 21(5):225-7
- Gibbs, R., Karlan, B., Haney, A.F., Nygaard, I.E., 2008. Danforth's Obstetrics and Gynecology 10th Edition. Lippincott William & Wilkins; 61: 1022-6

- Glud E, Kjaer S, Thomsen B, et al. 2004. Hormone therapy and the impact of estrogen intake on the risk of ovarian cancer. *Arch Intern Med*, 164(20):2253–2259.
- Gram IT, Lukanova A, Brill I, et al. 2012. Cigarette smoking and risk of histological subtypes of epithelial ovarian cancer in the EPIC cohort study. *Int J Cancer*, 130(9):2204–2210. doi:10.1002/ijc.26235
- Gronlund B, Dehn H, Hogdall CK, Engelholm SA, Jorgensen M, Norgaard-Pedersen B, Hogdall EV. 2005. Cancer-associated serum antigen level: a novel prognostic indicator for survival in patients with recurrent ovarian carcinoma. *Int J Gynecol Cancer*
- Guldberg R, Wehberg S, Skovlund CW, Mogensen O, Lidegaard O. 2013. Salpingectomy as standard at hysterectomy? A Danish cohort study, 1977-2010. *BMJ*, 3: e002845.
- Gutman SI, Piper M, Grant MD, et al. 2013. Progression-Free Survival: What Does It Mean for Psychological Well-Being or Quality of Life? [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US).
- Hankinson SE, Colditz GA, Hunter DJ, et al. 1995. A prospective study of reproductive factors and risk of epithelial ovarian cancer. *Cancer*, 76(2):284–290
- Helder-Woolderink J, Blok E, Vasen H, Hollema H, Mourits M, De Bock G. 2016. Ovarian cancer in Lynch syndrome; a systematic review. *Eur J Cancer.*, 55:65–73. doi:10.1016/j.ejca.2015.12.005
- Henderson, J.T, Webber, E.M, Sawaya, G.F. 2018. Screening for ovarian cancer updated evidence report and systematic review for the US preventive services task force. *JAMA J. Am. Med. Assoc*, 319, 595–606.
- Hennessy, B.T, Coleman, R.L, Markman, M. Ovarian cancer. *Lancet* 2009, 374, 1371–1382.
- Horowitz, N.S, Miller, A, Rungruang, B, Richard, S.D, Rodriguez, N, Bookman, M.A, Hamilton, C.A, Krivak, T.C, Maxwell, G.L. 2015. Does aggressive surgery improve outcomes? Interaction between preoperative disease burden and complex surgery in patients with advanced-stage ovarian cancer: An analysis of GOG 182. *J. Clin. Oncol*, 33, 937–943.

- Howlader, N, Noone, A.M, Krapcho, M, Miller, D, Brest, A, Yu, M, Ruhl, J, Tatalovich, Z, Mariotto, A, Lewis, D.R, et al. 2020. SEER Cancer Statistics Review, 1975–2017; National Cancer Institute: Bethesda, MD, USA.
- Huang L, Zhou Y, Cao XP, et al. 2017. KPNA2 is a potential diagnostic serum biomarker for epithelial ovarian cancer and correlates with poor prognosis. *Tumour Biol*, 39(6):1010428317706289.
- Hunn, J, Rodriguez, G.C. 2012. Ovarian cancer: Etiology, risk factors, and epidemiology. *Clin. Obs. Gynecol*, 55, 3–23.
- Jacobs, I.J, Menon, U, Ryan, A, Gentry-Maharaj, A, Burnell, M, Kalsi, J.K, Amso, N.N, Apostolidou, S, Benjamin, E, Cruickshank, D, et al. 2016. Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): A randomised controlled trial. *Lancet*, 387, 945–956.
- Jacobs, I, Prys Davies, A, Bridges, J, Stabile, I, Fay, T, Lower, A, Grudzinskas, J.G, Oram, D. 1993. Prevalence screening for ovarian cancer in postmenopausal women by CA 125 measurement and ultrasonography. *Br. Med. J*, 306, 1030–1034
- Jelovac, D, Armstrong, D.K. 2011. Recent progress in the diagnosis and treatment of ovarian cancer. *CA Cancer J. Clin*, 61, 183–203
- Jia D, Nagaoka Y, Katsumata M, Orsulic S. 2018. Inflammation is a key contributor to ovarian cancer cell seeding. *Sci Rep*, 8(1):12394. doi:10.1038/s41598-018-30261-8
- Jian-Lun, X., John, C., Edward, P., Thomas, L.R., Philip, C., Christine, C.J., Sandra S. 2012. Longitudinal evaluation of CA-125 velocity and prediction of ovarian cancer. *Gynecologic Oncology*;125:70–74.
- Jin C, Yang M, Han X, et al. 2019. Evaluation of the value of preoperative CYFRA21-1 in the diagnosis and prognosis of epithelial ovarian cancer in conjunction with CA125. *J Ovarian Res*, 12(1):114.
- Jing S, Chen Z, Xie F, et al. 2013. Analysis of prognostic factors of 57 cases of ovarian cancer. *Chinese Journal of Anatomy and Clinical Sciences*, 18(2):136-138.

- Kato S, Abarzua-Catalan L, Trigo C, et al. 2015. Leptin stimulates migration and invasion and maintains cancer stem-like properties in ovarian cancer cells: an explanation for poor outcomes in obese women. *Oncotarget*, 6(25):21100-21119.
- Kemkes. Kanker Dapat Dikendalikan, Menkes : Kuncinya Deteksi Dini. 2023. <https://www.kemkes.go.id/eng/rilis-kesehatan/kanker-dapat-dikendalikan-menkes-kuncinya-deteksi-dini>
- Kim, J, Coffey, D.M, Ma, L, Matzuk, M.M. 2015. The ovary is an alternative site of origin for high-grade serous ovarian cancer in mice. *Endocrinology*, 156, 1975–1981.
- Komatsu H, Oishi T, Itamochi H, et al. 2017. Serum Vascular Endothelial Growth Factor-A as a Prognostic Biomarker for Epithelial Ovarian Cancer. *Int J Gynecol Cancer*, 27(7):1325-1332.
- Koshiyama, M, Matsumura, N, Konishi, I. 2017. Subtypes of ovarian cancer and ovarian cancer screening. *Diagnostics*, 7, 12.
- Krivak TC, Tian C, Rose GS, Armstrong DK, Maxwell GL. 2009. A Gynecologic Oncology Group Study of serum CA-125 levels in patients with stage III optimally debulked ovarian cancer treated with intraperitoneal compared to intravenous chemotherapy: an analysis of patients enrolled in GOG 172. *Gynecol Oncol*. 2009 Oct;115(1):81-85. doi: 10.1016/j.ygyno.2009.06.021. Epub 2009 Jul 12. PMID: 19596139; PMCID: PMC4380179.
- Kurman, R.J, Shih, I.-M. 2011. Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer. shifting the paradigm. *Hum. Pathol*, 42, 918–931.
- Kurman, R.J, Shih, I.M. 2016. The dualistic model of ovarian carcinogenesis revisited, revised, and expanded. *Am. J. Pathol*, 186, 733–747.
- Kwon AY, Heo I, Lee HJ, et al. 2016. Sox10 expression in ovarian epithelial tumors is associated with poor overall survival. *VirchowsArch*, 468(5):597-605.
- Kwon M, Kim JH, Rybak Y, et al. 2016. Reduced expression of FILIP1L, a novel WNT pathway inhibitor, is associated with poor survival, progression and chemoresistance in ovarian cancer. *Oncotarget*, 7(47):77052-77070.
- Lacey JV Jr, Mink PJ, Lubin JH, et al. 2002. Menopausal hormone replacement therapy and risk of ovarian cancer. *Jama*, 288(3):334–341

- Lee M, Chang MY, Yoo H, Lee KE, Chay DB, Cho H, Kim S, Kim YT, Kim JH. 2016. Clinical Significance of CA125 Level after the First Cycle of Chemotherapy on Survival of Patients with Advanced Ovarian Cancer. *Yonsei Med J*, May;57(3):580-7
- Li, L., Tian, J., Zhang, L., Liu, L., Sheng, C., Huang, Y., Zheng, H., Song, F., Chen, K., 2021. Utility of preoperative inflammatory markers to distinguish epithelial ovarian cancer from benign ovarian masses. *J. Cancer* 12, 2687–2693. <https://doi.org/10.7150/JCA.51642>
- Li Z, Hong N, Robertson M, Wang C, Jiang G. 2017. Preoperative red cell distribution width and neutrophil-to-lymphocyte ratio predict survival in patients with epithelial ovarian cancer. *Sci Rep*,7:43001.
- Li Z, Yin H, Ren M, Shen Y. 2020. Prognostic Significance of CA125 Dynamic Change for Progression Free Survival in Patients with Epithelial Ovarian Carcinoma. *Med Sci Monit*, Sep 10;26:e925051
- Liu C, LI Li, Zhao B, et al. 2018. III C ~ IV stage epithelial ovarian cancer prognosis factors analysis. *International Journal of Gynecology & Obstetrics*, 45(06):50-53+59.
- Liu, S., Wu, M. and Wang, F. 2021. Research progress in prognostic factors and biomarkers of ovarian cancer, *Journal of Cancer*, 12(13), pp. 3976–3996. doi:10.7150/jca.47695.
- Liu Y, Chen S, Zheng C, et al. 2017. The prognostic value of the preoperative c-reactive protein/albumin ratio in ovarian cancer. *BMC Cancer*, 17(1):285.
- Lloyd, K.O, Yin, B.W.T, Kudryashov, V. 1997. Isolation and characterization of ovarian cancer antigen CA 125 using a new monoclonal antibody (VK-8): Identification as a mucin-type molecule. *Int. J. Cancer*, 71, 842–850.
- Lyu N, Wang Y, Wang J, Zhang Z, Kong W. 2018. Study on early diagnosis of epithelial ovarian cancer by analysis of plasma septin-9 and clusterin level. *J Cancer Res Ther*, 14(Supplement): S444-S449.
- Makar, A.P, Baekelandt, M, Tropé, C.O, Kristensen, G.B. 1995. The prognostic significance of residual disease, figo substage, tumor histology, and grade in patients with figo stage III ovarian cancer. *Gynecol. Oncol*, 56, 175–180.

- Makar, A., Kristensen, G.B., Kærn, J., Børner, O.P., Abeler, V.M., & Tropé, C.G. 1992. Prognostic value of pre- and postoperative serum CA 125 levels in ovarian cancer: New aspects and multivariate analysis. *International Journal of Gynecology & Obstetrics*, 40.
- Mallen A, Todd S, Robertson SE, Kim J, Sehovic M, Wenham RM, Extermann M, Chon HS. 2021. Impact of age, comorbidity, and treatment characteristics on survival in older women with advanced high grade epithelial ovarian cancer. *Gynecol Oncol*, Jun;161(3):693-699. doi: 10.1016/j.ygyno.2021.03.008. Epub 2021 Mar 31. PMID: 33812698.
- Markman, M., Federico, M., Liu, P., Hannigan, E.V., & Alberts, D.E. 2006. Significance of early changes in the serum CA-125 antigen level on overall survival in advanced ovarian cancer. *Gynecologic oncology*, 103 1, 195-8 .
- Markman M, Liu PY, Rothenberg ML, Monk BJ, Brady M, Alberts DS. 2006. Pretreatment CA-125 and risk of relapse in advanced ovarian cancer. *J Clin Oncol*, Mar 20;24(9):1454-8. doi: 10.1200/JCO.2005.04.7373. PMID: 16549840.
- Massi D, Susini T, Savino L, Boddi V, Amunni G, Colafranceschi M. 1996. Epithelial ovarian tumors in the reproductive age group: age is not an independent prognostic factor. *Cancer*, 77(6):1131–1136
- Mehner C, Oberg AL, Kalli KR, et al. 2015. Serine protease inhibitor Kazal type 1 (SPINK1) drives proliferation and anoikis resistance in a subset of ovarian cancers. *Oncotarget*, Nov;6(34):35737-35754. DOI: 10.18632/oncotarget.5927. PMID: 26437224; PMCID: PMC4742138.
- Mehra, K, Mehrad, M, Chen, E, Ning, G, Drapkin, R, McKeon, F.D, Xian, W, Crum, C.P. 2011. STICS, SCOUTs and p53 signatures; A new language for pelvic serous carcinogenesis. *Front. Biosci*, 3, 625–634.
- Meng X, Joosse SA, Müller V, et al. 2015. Diagnostic and prognostic potential of serum miR-7, miR-16, miR-25, miR-93, miR-182, miR-376a and miR-429 in ovarian cancer patients. *Br J Cancer*, 113(9):1358-1366.
- Meng X, Müller V, Milde-Langosch K, Trillsch F, Pantel K, Schwarzenbach H. 2016. Diagnostic and prognostic relevance of circulating exosomal miR-

373, miR-200a, miR-200b and miR-200c in patients with epithelial ovarian cancer. *Oncotarget*, 7(13):16923-16935.

Michel, S., Charles, D., Robin, F., Shirley, G., Jason, T., Ingegerd, H., Karl, E.H., Nicole, U. 2012. Evaluation of ovarian cancer remission markers Human Epididymis Protein 4, MMP7 and Mesothelin by comparison to the established marker CA-125. *Gynecology Oncology*;125:65-69.

Miao, Y., Yan, Q., Li, S., Li, B., & Feng, Y., 2016, Neutrophil to Lymphocyte Ratio and Platelet to Lymphocyte Ratio are Predictive of Chemotherapeutic Response and Prognosis in Epithelial Ovarian Cancer Patients Treated with Platinum-Based Chemotherapy, *Cancer Biomarkers*, 17(1), 33–40, <https://doi.org/10.3233/CBM-160614>.

Moebus V: KRCGWHCHKH: Evaluation of CA125 as a prognostic and predictive factor in ovarian cancer. *J Tumor Marker Oncol*

Mohammadian M, Ghafari M, Khosravi B, et al. 2017. Variations in the incidence and mortality of ovarian cancer and their relationship with the human development index in European Countries in 2012. *Biomed Res Ther*, 4(08):1541–1557. doi:10.15419/bmrat.v4i08.228

Momenimovahed, Z., Tiznobaik, A., Taheri, S., Salehiniya, H. 2019. Ovarian cancer in the world: epidemiology and risk factors. *Int J Womens Health* Volume 11, 287–299. <https://doi.org/10.2147/IJWH.S197604>

Montagnana, M., Danese, E., Ruzzenente, O., Bresciani, V., Nuzzo, T., Gelati, Matteo, G., Gian Luca, S., Massimo, F., Giuseppe, L and Gian, G.C. 2011. The ROMA (Risk Ovarian of Malignancy Algorithm) for estimating the risk of epithelial ovarian cancer in women presenting with pelvic mass: is it really useful? *Clin Chem Lab Med*,49(3):521-5.

Moore, R.G., MacLaughlan, S., Bast, R.B. 2010. Current State of Biomarker Development for Clinical Application in Epithelial Ovarian Cancer. *Gyn Onc*, 116: 240–245.

Morelli M, Venturella R, Mocciaro R, Di Cello A, Rania E, Lico D, et al. 2013. Prophylactic salpingectomy in premenopausal low-risk women for ovarian cancer: primum non nocere. *Gynecol Oncol*, 129: 444-51.

- Morgan, R.J, Armstrong, D.K, Alvarez, R.D, Bakkum-Gamez, J.N, Behbakht, K, Chen, L.M, Copeland, L, Crispens, M.A, De Rosa, M, Dorigo, O, et al. Ovarian cancer, version 1. 2016: Clinical practice guidelines in oncology. JNCCN J. Natl. Compr. Cancer Netw, 14, 1134–1163.
- Moschetta, M, George, A, Kaye, S.B, Banerjee, S. 2016. BRCA somatic mutations and epigenetic BRCA modifications in serous ovarian cancer. *Ann. Oncol*, 27, 1449–1455.
- Mucci LA, Dickman PW, Lambe M, et al. 2007. Gestational age and fetal growth in relation to maternal ovarian cancer risk in a Swedish cohort. *Cancer Epidemiol Prev Biomarkers*, 16 (9):1828–1832. doi:10.1158/1055-9965.EPI-06-0962
- Münstedt K, Krisch M, Sachsse S, Vahrson H. 1997. Serum CA 125 levels and survival in advanced ovarian cancer. *Archives of Gynecology and Obstetrics*, 259(3):117-123. DOI: 10.1007/bf02505319. PMID: 9187463.
- Narod, S. 2016. Can advanced-stage ovarian cancer be cured? *Nat. Rev. Clin. Oncol*, 13, 255–261.
- Nakamura H, Nagasaka K, Kawana K, et al. 2016. Expression of Par3 polarity protein correlates with poor prognosis in ovarian cancer. *BMC Cancer*, 16(1):897.
- Ness RB, Goodman MT, Shen C, Brunham RC. 2003. Serologic evidence of past infection with *Chlamydia trachomatis*, in relation to ovarian cancer. *J Infect Dis*, 187(7):1147–1152. doi:10.1086/368380
- Ness RB, Grisso JA, Cottreau C, et al. 2019. Factors related to inflammation of the ovarian epithelium and risk of ovarian cancer. *Epidemiology*. 2000;11(2):111–117.
- Nomelini RS, Carrijo Chiovato AF, Abdulmassih FBF, da Silva RC, Tavares-Murta BM, Murta EFC. Neutrophil-to-lymphocyte ratio and platelet count as prognostic factors in ovarian malignancies. *J Cancer Res Ther*, 15(6):1226-1230.
- Nossov, V, Amneus, M, Su, F, Lang, J, Janco, J.M.T, Reddy, S.T, Farias-Eisner, R. 2008. The early detection of ovarian cancer: From traditional methods to

- proteomics. Can we really do better than serum CA-125? *Am. J. Obs. Gynecol*, 199, 215–223.
- Nustad, K, Bast, R.C, O'brien, T.J, Nilsson, O, Seguin, P, Suresh, M.R, Saga, T, Nozawa, S, Børmer, O.P, de Bruijn, H.W.A, et al. 1996. Specificity and affinity of 26 monoclonal antibodies against the CA 125 antigen: First report from the ISOBM TD-1 workshop. *Tumor. Biol*, 17, 196–219.
- Nyvang GB, Mogensen O, Bichel P, Jakobsen A. Combined prognostic importance of CA 125, histopathologic grade and DNA-index in advanced ovarian cancer. *Eur J Gynaecol Oncol*
- Obermair A, Youlden DR, Baade PD, Janda M. 2014. The impact of riskreducing hysterectomy and bilateral salpingo-oophorectomy on survival in patients with a history of breast cancer- a populationbased data linkage study. *Int J Cancer*, 134: 2211-22
- Okła K, Surówka J, Frąszczak K, et al. 2018. Assessment of the clinicopathological relevance of mesothelin level in plasma, peritoneal fluid, and tumor tissue of epithelial ovarian cancer patients. *Tumour Biol*, 40(10):1010428318804937.
- Okunade KS, Adejimi AA, Ohazurike EO, Salako O, Osunwusi B, Adenekan MA, Ugwu AO, Soibi-Harry A, Dawodu O, Okunowo AA, Anorlu RI, Berek JS. 2021. Predictors of Survival Outcomes After Primary Treatment of Epithelial Ovarian Cancer in Lagos, Nigeria. *JCO Glob Oncol*, Jan;7:89-98. doi: 10.1200/GO.20.00450. PMID: 33449803; PMCID: PMC8081541.
- Oliver KE, Brady WE, Birrer M, Gershenson DM, Fleming G, Copeland LJ, Tewari K, Argenta PA, Mannel RS, Secord AA, Stephan JM, Mutch DG, Stehman FB, Muggia FM, Rose PG, Armstrong DK, Bookman MA, Burger RA, Farley JH. 2017. An evaluation of progression free survival and overall survival of ovarian cancer patients with clear cell carcinoma versus serous carcinoma treated with platinum therapy: An NRG Oncology/Gynecologic Oncology Group experience. *Gynecol Oncol*, Nov;147(2):243-249. doi: 10.1016/j.ygyno.2017.08.004. Epub 2017 Aug 12. PMID: 28807367; PMCID: PMC5697899.

- Osman N, O'Leary N, Mulcahy E, Barrett N, Wallis F, Hickey K, Gupta R. 2008. Correlation of serum CA125 with stage, grade and survival of patients with epithelial ovarian cancer at a single centre. *Ir Med J*, 101: 245–247
- Paoletti, X. et al. 2020. “Assessment of progression-free survival as a surrogate end point of overall survival in first-line treatment of ovarian cancer,” *JAMA Network Open*, 3(1). Available at: <https://doi.org/10.1001/jamanetworkopen.2019.18939>.
- Parmar MK, Ledermann JA, Colombo N, et al. 2003. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. *Lancet*, 361(9375): 2099-2106.
- Pavone, M.E., Lyttle, B. 2015. Endometriosis and ovarian cancer: links, risks, and challenges faced. *Int J Womens Health* 663. <https://doi.org/10.2147/IJWH.S66824>
- Peres LC, Cushing-Haugen KL, Anglesio M, Wicklund K, Bentley R, Berchuck A, Kelemen LE, Nazeran TM, Gilks CB, Harris HR, Huntsman DG, Schildkraut JM, Rossing MA, Köbel M, Doherty JA. 2018. Histotype classification of ovarian carcinoma: A comparison of approaches. *Gynecol Oncol*, Oct;151(1):53-60. doi: 10.1016/j.ygyno.2018.08.016. Epub 2018 Aug 16. PMID: 30121132; PMCID: PMC6292681.
- Petri AL, Hogdall E, Christensen IJ, Kjaer SK, Blaakaer J, Hogdall CK: Preoperative CA125 as a prognostic factor in stage I epithelial ovarian cancer. *APMIS*
- Piatek S, Panek G, Lewandowski Z, Bidzinski M, Piatek D, Kosinski P, Wielgos M. 2020. Rising serum CA-125 levels within the normal range is strongly associated recurrence risk and survival of ovarian cancer. *J Ovarian Res*, Sep 2;13(1):102. doi: 10.1186/s13048-020-00681-0. PMID: 32878632; PMCID: PMC7469284.
- Piek, J.M.J, Van Diest, P.J, Zweemer, R.P, Jansen, J.W, Poort-Keesom, R.J.J, Menko, F.H, Gille, J.J.P, Jongasma, A.P.M, Pals, G, Kenemans, P, et al. 2001. Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancer. *J. Pathol*, 195, 451–456.

- Pinto MP, Balmaceda C, Bravo ML, et al. 2018. Patient inflammatory status and CD4+/CD8+ intraepithelial tumor lymphocyte infiltration are predictors of outcomes in high-grade serous ovarian cancer. *Gynecol Oncol*, 151(1):10-17.
- Poole EM, Merritt MA, Jordan SJ, et al. 2013. Hormonal and reproductive risk factors for epithelial ovarian cancer by tumor aggressiveness. *Cancer Epidemiol Prev Biomarkers*. doi:10.1158/1055-9965.EPI-12-1183-T
- Prahm, K.P, Karlsen, M.A, Høgdall, E, Scheller, N.M, Lundvall, L, Nedergaard, L, Christensen, I.J, Høgdall, C. 2015. The prognostic value of dividing epithelial ovarian cancer into type I and type II tumors based on pathologic characteristics. *Gynecol. Oncol*, 136, 205–211
- Prat J. 2014. FIGO Committee on Gynecologic Oncology. Staging classification for cancer of the ovary, fallopian tube, and peritoneum. *Int J Gynaecol Obstet*, Jan;124(1):1-5.
- Qiu JJ, Lin XJ, Tang XY, Zheng TT, Lin YY, Hua KQ. 2018. Exosomal Metastasis-Associated Lung Adenocarcinoma Transcript 1 Promotes Angiogenesis and Predicts Poor Prognosis in Epithelial Ovarian Cancer. *Int J Biol Sci*, 14(14):1960-1973
- Rahmani K, Moradi-Lakeh M, Mansori K, Bidokhti F, AsadiLari M. 2018. global inequalities in incidence and mortality of ovarian cancer and associated factors: an ecological study. *Alzheimers Park Res Ther*, 1:1.
- Ranjit, K., Mushra, M., Jitendra, K.S., Akhileswari, N., Mohammad, A., Arun, K. 2009. Evaluation of the Significance of CA-125 Levels in Patients with Epithelial Ovarian Cancer in Bihar,India. *Clinical Ovarian Cancer*, Vol.2,No.2,118-120.
- Rasmussen CB, Jensen A, Albieri V, Andersen KK, Kjaer SK. 2017. Is pelvic inflammatory disease a risk factor for Ovarian cancer? *Cancer Epidemiol Biomarkers Prev*, 26(1):104–109. doi:10.1158/1055-9965.EPI-16-0459
- Razi S, Ghoncheh M, Mohammadian-Hafshejani A, Aziznejhad H, Mohammadian M, Salehiniya H. 2016. The incidence and mortality of ovarian cancer and their relationship with the human development index in Asia. *Cancermedicalscience*, 10:628.

- Reade CJ, Finlayson S, McAlpine J, Tone AA, Fung-Kee-Fung M, Ferguson SE. 2013. Risk reducing salpingectomy in Canada: a survey of obstetrician-gynaecologists. *J Obstet Gynaecol Can*, 35: 627-34.
- Redman CW, Blackledge GR, Kelly K, Powell J, Buxton EJ, Luesley DM. 1990. Early serum CA125 response and outcome in epithelial ovarian cancer. *Eur J Cancer*, 26(5):593-596.
- Reid BM, Permuth JB, Sellers TA. 2017. Epidemiology of ovarian cancer: a review. *Cancer Biol Med*, 14(1):9. doi:10.20892/j.issn.2095-3941.2016.0084
- Richard, G.M., Micahel, C.M., Elizabeth, E.E., Karen, H.L., Robert, C.B., Geralyn, L.M. 2012. Serum Level of the Ovarian Cancer Biomarker HE-4 are Decreased in Pregnancy and Increase with Age. *American Journal Obstetric Gynecology*; 206-349,e1-7.
- Riedinger JM, Wafflart J, Ricolleau G, Eche N, Larbre H, Basuyau JP, Dalifard I, Hacene K, Pichon MF. CA 125 half-life and CA 125 nadir during induction chemotherapy are independent predictors of epithelial ovarian cancer outcome: results of a French multicentric study. *Ann Oncol*
- Ries LA. 1993. Ovarian cancer. Survival and treatment differences by age. *Cancer*, 71(2 Suppl):524–529.
- Risch HA, Howe GR. 1995. Pelvic inflammatory disease and the risk of epithelial ovarian cancer. *Cancer Epidemiol Biomarkers Prev*, 4(5):447–451
- Rocconi RP, Matthews KS, Kemper MK, et al. The timing of normalization of CA-125 levels during primary chemotherapy is predictive of survival in patients with epithelial ovarian cancer. *Gynecol Oncol*.
- Rosen, B, Laframboise, S, Ferguson, S, Dodge, J, Bernardini, M, Murphy, J, Segev, Y, Sun, P, Narod, S.A. 2014. The impacts of neoadjuvant chemotherapy and of debulking surgery on survival from advanced ovarian cancer. *Gynecol. Oncol*, 134, 462–467
- Rosen, D.G. 2009. Ovarian cancer: pathology, biology, and disease models. *Front Biosci Volume*, 2089. <https://doi.org/10.2741/3364>
- Rossing MA, Cushing-Haugen KL, Wicklund KG, Doherty JA, Weiss NS. 2008. Risk of epithelial ovarian cancer in relation to benign ovarian conditions and ovarian surgery. *Cancer Causes Control*, 19(10):1357.

- Roy, H.K, Khandekar, J.D. 2007. Biomarkers for the early detection of cancer: An inflammatory concept. *Arch. Intern. Med*, 167, 1822–1824
- Rustin GJ, Vergote I, Eisenhauer E, et al. 2011. Gynecological Cancer Intergroup. Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG). *Int J Gynecol Cancer*, 21(2):419-423. doi:10.1097/IGC.0b013e3182070f17
- Salazar-Martinez, E., Lazcano-Ponce, E.C., Gonzalez Lira-Lira, G., Escudero-De los Rios, P., Salmeron-Castro, J., Hernandez-Avila, M. 1999. Reproductive factors of ovarian and endometrial cancer risk in a high fertility population in Mexico. *Cancer res.* 59, 3658–62.
- Schorge, J.O., Hoffman, B.L., Schaffer, J.I., Halvorson, L.M., Bradshaw, K.D., Cunningham, F.G and Calver, L.E. 2008. *Williams Gynecology Tenth Edition*. The McGraw-Hill Companies, Inc, 36 Williams Gynecology, 2e
- Schummer, M., Drescher, C., Forrest, R., Gough, S., Thorpe, J., Hellstrom, I., Hellstrom, E. and Urban, N. 2012. Evaluation of Ovarian Cancer Remission Markers HE-4, MMP7 and Mesothelin by Comparison to the Established Marker CA-125. *Gyn Onc*, 125 : 65–69
- Schiavone, M.B, Herzog, T.J, Lewin, S.N, Deutsch, I, Sun, X, Burke, W.M, Wright, J.D. 2011. Natural history and outcome of mucinous carcinoma of the ovary. *Am. J. Obstet. Gynecol*, 205, 480.e1–480.e8
- Seung-Chul Y, Jong-Hyuck Y, Mi-Ok L, et al. 2009. Significance of postoperative CA-125 decline after cytoreductive surgery in stage III C/IV ovarian cancer. *J Gynecol Oncol*, 19(3):169–72
- Sevelda P, Schemper M, Spona J: CA 125 as an independent prognostic factor for survival in patients with epithelial ovarian cancer. *Am J Obstet Gynecol*
- Sharma S. 2009. Tumor markers in clinical practice: General principles and guidelines. *Indian J Med Paediatr Oncol*, Jan;30(1):1-8
- Siegel RL, Miller KD, Jemal A. 2020. Cancer statistics, 2020. *CA Cancer J Clin*, Jan;70(1):7-30.

- Sköld C, Bjørge T, Ekblom A, et al. 2018. Preterm delivery is associated with an increased risk of epithelial ovarian cancer among parous women. *Int J Cancer*, 143:1858–1867. doi:10.1002/ijc.31581
- Soegaard M, Jensen A, Hogdall E, et al. 2007. Different risk factor profiles for mucinous and nonmucinous ovarian cancer: results from the Danish MALOVA study. *Cancer Epidemiol Biomarkers Prev*, 16(6):1160–1166. doi:10.1158/1055-9965.EPI-07-0089
- Sölétormos G, Duffy MJ, Hassan SOA, et al. 2016. Clinical use of cancer biomarkers in epithelial ovarian cancer: Updated guidelines from the European Group on Tumor Markers. *Int J Gynecol Cancer*, 26(1):43–51
- Sopik, V, Rosen, B, Giannakeas, V, Narod, S.A. 2015. Why have ovarian cancer mortality rates declined? Part III. Prospects for the future. *Gynecol. Oncol*, 138, 757–761.
- Sopo M, Anttila M, Hämäläinen K, et al. 2019. Expression profiles of VEGF-A, VEGF-D and VEGFR1 are higher in distant metastases than in matched primary high grade epithelial ovarian cancer. *BMC Cancer*, 19(1):584.
- Sopo M, Sallinen H, Hämäläinen K, et al. 2020. High expression of Tie-2 predicts poor prognosis in primary high grade serous ovarian cancer. *PLoS One*, 15(11): e0241484
- Sowannakul A, Rodpenpear N, Ekbhum P, Tantitamit T. 2023. Prognostic Value of The Neutrophil-to-Lymphocyte Ratio, Platelet-to-Lymphocyte Ratio, and Platelet Count for Platinum-Sensitive Recurrent Epithelial Ovarian Cancer. *Asian Pac J Cancer Prev*, Nov 1;24(11):3765-3771. doi: 10.31557/APJCP.2023.24.11.3765. PMID: 38019234; PMCID: PMC10772778.
- Stewart LM, Holman CAJ, Aboagye-Sarfo P, Finn JC, Preen DB, Hart R. 2013. In vitro fertilization, endometriosis, nulliparity and ovarian cancer risk. *Gynecol Oncol*, 128(2):260–264. doi:10.1016/j.ygyno.2012.10.023
- Sun Y, Hu L, Zheng H, et al. 2015. MiR-506 inhibits multiple targets in the epithelial-to-mesenchymal transition network and is associated with good prognosis in epithelial ovarian cancer. *J Pathol*, 235(1):25-36.

- Szafron LM, Balcerak A, Grzybowska EA, et al. 2015. The putative oncogene, CRNDE, is a negative prognostic factor in ovarian cancer patients. *Oncotarget*, 6(41):43897-43910
- Tai H, Wu Z, Sun S, Zhang Z, Xu C. 2018. FGFR1 Promotes Ovarian Cancer Progression by Crosstalk with Hedgehog Signaling. *J Immunol Res*, 2018/7438608.
- Tian F, Jia L, Chu Z, Han H, Zhang Y, Cai J. 2018. MicroRNA-519a inhibits the proliferation and promotes the apoptosis of ovarian cancer cells through targeting signal transducer and activator of transcription 3. *Exp Ther Med*, 15(2):1819-1824.
- Tong X, Barbour M, Hou K, et al. 2016. Interleukin-33 predicts poor prognosis and promotes ovarian cancer cell growth and metastasis through regulating ERK and JNK signaling pathways. *Mol Oncol*, 10(1):113-125.
- Torre, L.A, Trabert, B, DeSantis, C.E, Miller, K.D, Samimi, G, Runowicz, C.D, Gaudet, M.M, Jemal, A, Siegel, R.L. 2018. Ovarian cancer statistics, 2018. *CA Cancer J. Clin*, 68, 284–296.
- Tung K, Goodman M, Wu A, et al. 2003. Reproductive factors and epithelial ovarian cancer risk by histologic type: a multiethnic case-control study. *Am J Epidemiol*, 158(7):629–638.
- Van Der Burg, Lammes FB, van Putten WL, Stoter G. Ovarian cancer: The prognostic value of the serum half-life of CA125 during induction chemotherapy. *Gynecol Oncol*
- Van Haaften-Day, C, Shen, Y, Xu, F, Yu, Y, Berchuck, A, Havrilesky, L.J, de Bruijn, H.W.A, van der Zee, A.G.J, Bast, R.C, Hacker, N.F. 2001. OVXL, macrophage-colony stimulating factor, and CA-125-II as tumor markers for epithelial ovarian carcinoma a critical appraisal. *Cancer*, 92, 2837–2844.
- Vos MC, Hollemans E, Ezendam N, et al. 2016. MMP-14 and CD44 in Epithelial-to-Mesenchymal Transition (EMT) in ovarian cancer. *J Ovarian Res*, 9(1):53
- WCRF International. "Ovarian cancer statistics/World Cancer Research Fund International".

- Weiderpass E, Sandin S, Inoue M, et al. 2012. Risk factors for epithelial ovarian cancer in Japan - results from the Japan Public Health Center-based Prospective Study cohort. *Int J Oncol*, 40(1):21–30. doi:10.3892/ijo.2011.1194
- Wohlmuth C, Djedovic V, Kjaer SK, Jensen A, Glasspool R, Roxburgh P, DeFazio A, Johnatty SE, Webb PM, Modugno F, Lambrechts D, Schildkraut JM, Berchuck A, Thomsen LCV, Bjorge L, Høgdall E, Høgdall CK, Goode EL, Winham SJ, Matsuo K, Karlan BY, Lester J, Goodman MT, Thompson PJ, Pejovic T, Riggan MJ, Lajkosz K, Tone A, May T. 2022. CA-125 Levels Are Predictive of Survival in Low-Grade Serous Ovarian Cancer-A Multicenter Analysis. *Cancers (Basel)*, Apr 13;14(8):1954. doi: 10.3390/cancers14081954. PMID: 35454861; PMCID: PMC9024456.
- World Cancer Report 2014. World Health Organization. 2014. Chapter 5.12. ISBN 978-9283204299.
- Yin, B.W.T, Lloyd, K.O. 2001. Molecular cloning of the CA125 ovarian cancer antigen: Identification as a new mucin, MUC16. *J. Biol. Chem*, 276, 27371–27375.
- Yongjung, P., Jong-Han, L., Duck, J.H., Eun, Y.L., Hyon-Suk, K. 2011. Diagnostic Performances of HE-4 and CA-125 for the Detection of Ovarian Cancer from Patients with Various Gynecologic and Non-Gynecologic Diseases. *Clinical Biochemistry*;44: 884–888.
- Yu W, Ye Z, Fang X, Jiang X, Jiang Y. 2019. Preoperative albumin-to-fibrinogen ratio predicts chemotherapy resistance and prognosis in patients with advanced epithelial ovarian cancer. *J Ovarian Res*, 12(1):88.
- Zamwar UM, Anjankar AP. 2022. Aetiology, Epidemiology, Histopathology, Classification, Detailed Evaluation, and Treatment of Ovarian Cancer. *Cureus*, Oct 21;14(10):e30561. doi: 10.7759/cureus.30561. PMID: 36415372; PMCID: PMC9676071
- Zanotti L, Romani C, Tassone L, et al. 2017. MAL gene overexpression as a marker of high-grade serous ovarian carcinoma stem-like cells that predicts chemoresistance and poor prognosis. *BMC Cancer*, 17(1):366.

- Zeppernick, F, Meinhold-Heerlein, I, Meinhold-Heerlein, Á.I. 2014. The new FIGO staging system for ovarian, fallopian tube, and primary peritoneal cancer. *Arch. Gynecol Obs*, 290, 839–842
- Zhao H, Guo E, Hu T, et al. 2016. KCNN4 and S100A14 act as predictors of recurrence in optimally debulked patients with serous ovarian cancer. *Oncotarget*, 7(28):43924-43938.
- Zheng Q, Wang P, Hui R, et al. 2009. Cox regression analysis of prognostic factors in ovarian cancer patients. *Cancer*, 16(02):99-102.
- Žilovič, Diana; Čiurlienė, Rūta; Sabaliauskaitė, Rasa; Jarmalaitė, Sonata. 2021. "Future Screening Prospects for Ovarian Cancer". *Cancers*. 13 (15): 3840. doi:10.3390/cancers13153840
- Zuberi M, Mir R, Das J, et al. 2015. Expression of serum miR-200a, miR-200b, and miR-200c as candidate biomarkers in epithelial ovarian cancer and their association with clinicopathological features. *Clin Transl Oncol*, 17(10):779-787.
- Zurawski VR Jr, Orjasetter H, Andersen A, Jellum E. 1988. Elevated serum CA 125 levels prior to diagnosis of ovarian neoplasia: relevance for early detection of ovarian cancer. *Int J Cancer*, 42(5):677-680.